The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Pathophysiology of NASH in endocrine diseases
Endocr Connect. 2021 Jan 1;EC-20-0490.R1. doi: 10.1530/EC-20-0490.Online ahead of print.
Karim Gariani1, François R Jornayvaz2
Author information
1K Gariani, Service of Endocrinology, Diabetes, Hypertension and Nutrition, Geneva University Hospital, Geneva, 1205, Switzerland.
2F Jornayvaz, Service of Endocrinology, Diabetes, Hypertension and Nutrition, Hopitaux Universitaires de Genève, geneva, Switzerland.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the industrialized world. NAFLD encompasses a whole spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. The latter can lead to hepatocellular carcinoma. Furthermore, NASH is the most rapidly increasing indication for liver transplantation in western countries and therefore represents a global health issue. The pathophysiology of NASH is complex and includes multiple parallel hits. NASH is notably characterized by steatosis as well as evidence of hepatocyte injury and inflammation, with or without fibrosis. NASH is frequently associated with type 2 diabetes and conditions associated with insulin resistance. Moreover, NASH may also be found in many other endocrine diseases such as polycystic ovary syndrome, hypothyroidism, male hypogonadism, growth hormone deficiency or glucocorticoid excess, for example. In this review, we will discuss the pathophysiology of NASH associated with different endocrinopathies.